McKesson reports Q2 adjusted EPS $6.23, consensus $6.11

Reports Q2 revenue $77.22B, consensus $75.83M. “McKesson delivered second quarter results above expectations, demonstrating continued progress against our company priorities,” said Brian Tyler, chief executive officer. “This performance and continued momentum reflect the dedication and contribution of our McKesson team members. The continued strength of our differentiated capabilities in our oncology and biopharma services platforms positions McKesson to deliver sustainable growth and compelling long-term shareholder value.”